INSM vs. PBH, RARE, CRNX, BHVN, MDGL, HCM, BHC, ALKS, ALPN, and XENE
Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Prestige Consumer Healthcare (PBH), Ultragenyx Pharmaceutical (RARE), Crinetics Pharmaceuticals (CRNX), Biohaven (BHVN), Madrigal Pharmaceuticals (MDGL), HUTCHMED (HCM), Bausch Health Companies (BHC), Alkermes (ALKS), Alpine Immune Sciences (ALPN), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
Insmed (NASDAQ:INSM) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.
Prestige Consumer Healthcare has a net margin of -7.11% compared to Insmed's net margin of -245.59%. Prestige Consumer Healthcare's return on equity of 14.09% beat Insmed's return on equity.
Insmed has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.
In the previous week, Insmed had 1 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 4 mentions for Insmed and 3 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 1.34 beat Insmed's score of 0.97 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.
100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 4.6% of Insmed shares are owned by insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Insmed received 19 more outperform votes than Prestige Consumer Healthcare when rated by MarketBeat users. However, 70.67% of users gave Prestige Consumer Healthcare an outperform vote while only 64.73% of users gave Insmed an outperform vote.
Prestige Consumer Healthcare has higher revenue and earnings than Insmed. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.
Insmed presently has a consensus price target of $44.92, suggesting a potential upside of 75.80%. Prestige Consumer Healthcare has a consensus price target of $110.00, suggesting a potential upside of 57.14%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Insmed is more favorable than Prestige Consumer Healthcare.
Summary
Insmed and Prestige Consumer Healthcare tied by winning 9 of the 18 factors compared between the two stocks.
Get Insmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
